Pharmafile Logo

Rob White

- PMLiVE

Baxter taps Coherus for Enbrel biosimilar

Deal to develop copy of Amgen and Pfizer's arthritis and psoriasis is worth up to $246m

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

- PMLiVE

Outcomes shape the new European payer networks

In the new commercial reality of cost-constrained healthcare environments the payer is everywhere

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Building and delivering market access capabilities in emerging markets

Local skills gaps must be addressed if the potential of the BRIC countries is to be realised

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Modern values in healthcare

Understanding the new concepts and processes of value will be the first steps towards adapting to a new healthcare environment

- PMLiVE

Lonza ends biosimilars deal with Teva

Chemical firm cuts losses after four-year development deal

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

- PMLiVE

Interview: David Haslam, NICE

The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

- PMLiVE

Sandoz takes short route for biosimilar Enbrel approval

Novartis subsidiary initiates late-stage trial to support use in chronic plaque-type psoriasis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links